MRNA - Why Moderna Stock Is a No-Brainer Buy Right Now
2024-06-10 05:50:00 ET
Some investors might view Moderna (NASDAQ: MRNA) as a shooting star that shined bright for a while then flamed out. In 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only $4 billion this year.
The real story for Moderna is much better than that steep sales decline reflects. Here's why the biotech stock is a no-brainer buy right now.
It's no exaggeration to say that Moderna is at an inflection point. The company's previous success stemmed entirely from its COVID-19 vaccine Spikevax. That's changing.
For further details see:
Why Moderna Stock Is a No-Brainer Buy Right Now